ReviewJournal of innate immunity2013
Pulmonary surfactant protein D in first-line innate defence against influenza A virus infections.
Review in Journal of innate immunity, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 41 citations in OpenAlex.
- Decoding SP-D and glycan binding mechanisms using a novel computational workflow.Biophysical journal · 2025Article
- Review
- Surfactant protein D is a biomarker of influenza-related pediatric lung injury.Pediatric pulmonology · 2022Article
- Pattern Recognition Proteins: First Line of Defense Against Coronaviruses.Frontiers in immunology · 2021Review
- Human Surfactant Protein D Binds Spike Protein and Acts as an Entry Inhibitor of SARS-CoV-2 Pseudotyped Viral Particles.Frontiers in immunology · 2021Article
- Ozone-Induced Oxidative Stress, Neutrophilic Airway Inflammation, and Glucocorticoid Resistance in Asthma.Frontiers in immunology · 2021Review
- Pulmonary Surfactant and Drug Delivery: An Interface-Assisted Carrier to Deliver Surfactant Protein SP-D Into the Airways.Frontiers in bioengineering and biotechnology · 2020Article
- Mechanisms of Bacterial Superinfection Post-influenza: A Role for Unconventional T Cells.Frontiers in immunology · 2019Review
- Mutation S110L of H1N1 Influenza Virus Hemagglutinin: A Potent Determinant of Attenuation in the Mouse Model.Frontiers in immunology · 2019Article
- Enhanced Antiviral Activity of Human Surfactant Protein D by Site-Specific Engineering of the Carbohydrate Recognition Domain.Frontiers in immunology · 2019Article
- TGF beta inhibits expression of SP-A, SP-B, SP-C, but not SP-D in human alveolar type II cells.Biochemical and biophysical research communications · 2018Article
- The impact of respiratory viruses on lung health after preterm birth.European clinical respiratory journal · 2018Review
- Port d'Entrée for Respiratory Infections - Does the Influenza A Virus Pave the Way for Bacteria?Frontiers in microbiology · 2017Review
- Phylogenetically distinct equine influenza viruses show different tropism for the swine respiratory tract.The Journal of general virology · 2015Article
- The Role of Surfactant in Lung Disease and Host Defense against Pulmonary Infections.Annals of the American Thoracic Society · 2015Review
- The roles of direct recognition by animal lectins in antiviral immunity and viral pathogenesis.Molecules (Basel, Switzerland) · 2015Review
- Interferon-λ: Inters Ferocity or Inter-Ferocities?Journal of innate immunity · 2015Article
- Surveillance and countermeasures in innate immunity.Journal of innate immunity · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Influenza A viruses (IAV) cause respiratory tract infections annually associated with excess mortality and morbidity. Nonspecific, innate immune mechanisms play a key role in protection against viral invasion at early stages of infection. A soluble protein present in mucosal secretions of the lung, surfactant protein D (SP-D), is an important component of this initial barrier that helps to prevent and limit IAV infections of the respiratory epithelium. This collagenous C-type lectin binds IAVs and thereby inhibits attachment and entry of the virus but also contributes to enhanced clearance of SP-D-opsonized virus via interactions with phagocytic cells. In addition, SP-D modulates the inflammatory response and helps to maintain a balance between effective neutralization/killing of IAV, and protection against alveolar damage resulting from IAV-induced excessive inflammatory responses. The mechanisms of interaction between SP-D and IAV not only depend on the structure and binding properties of SP-D but also on strain-specific features of IAV, and both issues will be discussed. SP-D from pigs exhibits distinct anti-IAV properties and is discussed in more detail. Finally, the potential of SP-D as a prophylactic and/or therapeutic antiviral agent to protect humans against infections by IAV is discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.